| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |